Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAI plus gemtuzumab ozogamicin for newly diagnosed CD33-positive acute myeloid leukemia
2007-005248-26Phase 2Completed
- Sponsor
- Azienda Ospedaliera di Perugia
- Start
- Apr 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemtuzumab ozogamicin, fludarabine, cytarabine and idarubicin in acute myeloid leukemia (AML), sponsored by Azienda Ospedaliera di Perugia. Primary endpoints: Feasibility, Composite remission rate and 4 more. Started Apr 2008; status: completed.
02
Drugs
gemtuzumab ozogamicinfludarabinecytarabineidarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2007-005248-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005248-26.